Jiang Ting, Liu Kun, Chen Zexin
Department of Blood Transfusion, Chongqing Emergency Medical Center, Chongqing University Central Hospital, Chongqing, China.
Key Laboratory of Clinical Laboratory Dignostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, China.
Front Surg. 2022 Jul 21;9:927787. doi: 10.3389/fsurg.2022.927787. eCollection 2022.
There is no consensus on the effect of red blood cell transfusion on colorectal cancer (CRC). This study examined the impact of perioperative red blood cell transfusion on postoperative complications, recurrence, and mortality in patients with CRC.
In this retrospective cohort study, 219 CRC patients admitted to Chongqing Emergency Medical Center, and Chongqing University Central Hospital from 2008 to 2019 were divided into transfusion ( = 75) and non-transfusion ( = 144) groups. Univariate and multivariate Logistic regression analysis were used to analyze the effects of blood transfusion on the severity of postoperative complications in patients with CRC, and univariate and multivariate Cox regression was performed to analyze the effects of blood transfusion on postoperative death and recurrence.
Twenty-two (29.33%) patients in the transfusion group were intermediate or advanced severity of postoperative complications, 31 (41.33%) patients died in the transfusion group, and 55 (73.33%) patients occurred recurrence of the CRC, with the median follow-up time being 24.57(14.50,36.37) months. Our result showed that perioperative red blood cell transfusion was associated with an increased risk of intermediate or advanced severity of postoperative complications in CRC patients [odds ratio (OR) = 3.368, 95% CI, 1.146-9.901]. And perioperative red blood cell transfusion increased the risk of postoperative death [hazard ratio (HR) = 2.747, 95% CI, 1.048-7.205] and recurrence in patients with CRC (HR = 2.168, 95% CI, 1.192-3.943).
Our finding demonstrated that perioperative red blood cell transfusion was associated with severity of complications, recurrence, and death in CRC patients. However, further studies are still needed to confirm the adverse effects of red blood cell transfusions in CRC patients.
关于红细胞输注对结直肠癌（CRC）的影响尚无共识。本研究探讨围手术期红细胞输注对CRC患者术后并发症、复发及死亡率的影响。
在这项回顾性队列研究中，将2008年至2019年入住重庆急救医疗中心和重庆大学附属中心医院的219例CRC患者分为输血组（n = 75）和非输血组（n = 144）。采用单因素和多因素Logistic回归分析输血对CRC患者术后并发症严重程度的影响，并进行单因素和多因素Cox回归分析输血对术后死亡和复发的影响。
输血组22例（29.33%）患者术后并发症为中度或重度，输血组31例（41.33%）患者死亡，55例（73.33%）患者发生CRC复发，中位随访时间为24.57（14.50，36.37）个月。我们的结果表明，围手术期红细胞输注与CRC患者术后中度或重度并发症风险增加相关[比值比（OR）= 3.368，95%可信区间（CI），1.146 - 9.901]。围手术期红细胞输注增加了CRC患者术后死亡风险[风险比（HR）= 2.747，95% CI，1.048 - 7.205]和复发风险（HR = 2.168，95% CI，1.192 - 3.943）。
我们的研究结果表明，围手术期红细胞输注与CRC患者的并发症严重程度、复发和死亡相关。然而，仍需要进一步研究来证实红细胞输注对CRC患者的不良影响。
